These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 25701027)
1. Inhibition of metastasis and growth of breast cancer by pH-sensitive poly (β-amino ester) nanoparticles co-delivering two siRNA and paclitaxel. Tang S; Yin Q; Su J; Sun H; Meng Q; Chen Y; Chen L; Huang Y; Gu W; Xu M; Yu H; Zhang Z; Li Y Biomaterials; 2015 Apr; 48():1-15. PubMed ID: 25701027 [TBL] [Abstract][Full Text] [Related]
2. Co-delivery of doxorubicin and RNA using pH-sensitive poly (β-amino ester) nanoparticles for reversal of multidrug resistance of breast cancer. Tang S; Yin Q; Zhang Z; Gu W; Chen L; Yu H; Huang Y; Chen X; Xu M; Li Y Biomaterials; 2014 Jul; 35(23):6047-59. PubMed ID: 24797883 [TBL] [Abstract][Full Text] [Related]
3. Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles. Shen J; Sun H; Xu P; Yin Q; Zhang Z; Wang S; Yu H; Li Y Biomaterials; 2013 Feb; 34(5):1581-90. PubMed ID: 23146437 [TBL] [Abstract][Full Text] [Related]
4. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles. Feng Q; Yu MZ; Wang JC; Hou WJ; Gao LY; Ma XF; Pei XW; Niu YJ; Liu XY; Qiu C; Pang WH; Du LL; Zhang Q Biomaterials; 2014 Jun; 35(18):5028-38. PubMed ID: 24680191 [TBL] [Abstract][Full Text] [Related]
5. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes. Jin M; Jin G; Kang L; Chen L; Gao Z; Huang W Int J Nanomedicine; 2018; 13():2405-2426. PubMed ID: 29719390 [TBL] [Abstract][Full Text] [Related]
6. Systemic siRNA Delivery with a Dual pH-Responsive and Tumor-targeted Nanovector for Inhibiting Tumor Growth and Spontaneous Metastasis in Orthotopic Murine Model of Breast Carcinoma. Fan B; Kang L; Chen L; Sun P; Jin M; Wang Q; Bae YH; Huang W; Gao Z Theranostics; 2017; 7(2):357-376. PubMed ID: 28042340 [TBL] [Abstract][Full Text] [Related]
7. pH-Sensitive Nano-Complexes Overcome Drug Resistance and Inhibit Metastasis of Breast Cancer by Silencing Akt Expression. Yin J; Lang T; Cun D; Zheng Z; Huang Y; Yin Q; Yu H; Li Y Theranostics; 2017; 7(17):4204-4216. PubMed ID: 29158820 [TBL] [Abstract][Full Text] [Related]
8. Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel. Yu H; Xu Z; Chen X; Xu L; Yin Q; Zhang Z; Li Y Macromol Biosci; 2014 Jan; 14(1):100-9. PubMed ID: 23966347 [TBL] [Abstract][Full Text] [Related]
9. Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer. Yin T; Wang L; Yin L; Zhou J; Huo M Biomaterials; 2015 Aug; 61():10-25. PubMed ID: 25996409 [TBL] [Abstract][Full Text] [Related]
10. Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis. Chen X; Zhang Y; Tang C; Tian C; Sun Q; Su Z; Xue L; Yin Y; Ju C; Zhang C Int J Pharm; 2017 Aug; 529(1-2):102-115. PubMed ID: 28642204 [TBL] [Abstract][Full Text] [Related]
11. Acetal-linked paclitaxel prodrug micellar nanoparticles as a versatile and potent platform for cancer therapy. Gu Y; Zhong Y; Meng F; Cheng R; Deng C; Zhong Z Biomacromolecules; 2013 Aug; 14(8):2772-80. PubMed ID: 23777504 [TBL] [Abstract][Full Text] [Related]
12. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model. Devalapally H; Shenoy D; Little S; Langer R; Amiji M Cancer Chemother Pharmacol; 2007 Mar; 59(4):477-84. PubMed ID: 16862429 [TBL] [Abstract][Full Text] [Related]
13. Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice. Jin M; Hou Y; Quan X; Chen L; Gao Z; Huang W Int J Nanomedicine; 2021; 16():5479-5494. PubMed ID: 34413645 [TBL] [Abstract][Full Text] [Related]
14. Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Yu YH; Kim E; Park DE; Shim G; Lee S; Kim YB; Kim CW; Oh YK Eur J Pharm Biopharm; 2012 Feb; 80(2):268-73. PubMed ID: 22108492 [TBL] [Abstract][Full Text] [Related]
15. Cell-penetrating peptide mimicking polymer-based combined delivery of paclitaxel and siRNA for enhanced tumor growth suppression. Jang YL; Yun UJ; Lee MS; Kim MG; Son S; Lee K; Chae SY; Lim DW; Kim HT; Kim SH; Jeong JH Int J Pharm; 2012 Sep; 434(1-2):488-93. PubMed ID: 22613208 [TBL] [Abstract][Full Text] [Related]
16. Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer. Luo K; Gao Y; Yin S; Yao Y; Yu H; Wang G; Li J Acta Biomater; 2021 Oct; 134():649-663. PubMed ID: 34289420 [TBL] [Abstract][Full Text] [Related]
17. Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo. Zhan C; Wei X; Qian J; Feng L; Zhu J; Lu W J Control Release; 2012 Jun; 160(3):630-6. PubMed ID: 22410115 [TBL] [Abstract][Full Text] [Related]
18. Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ɛ-caprolactone) nanoparticles: In vitro and in vivo evaluation. Xin H; Chen L; Gu J; Ren X; Wei Z; Luo J; Chen Y; Jiang X; Sha X; Fang X Int J Pharm; 2010 Dec; 402(1-2):238-47. PubMed ID: 20934500 [TBL] [Abstract][Full Text] [Related]
19. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Yadav S; van Vlerken LE; Little SR; Amiji MM Cancer Chemother Pharmacol; 2009 Mar; 63(4):711-22. PubMed ID: 18618115 [TBL] [Abstract][Full Text] [Related]
20. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy. Li TS; Yawata T; Honke K Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]